<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028964</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069154</org_study_id>
    <secondary_id>UCSF-CRO-97755</secondary_id>
    <secondary_id>UCSF-IND-54870</secondary_id>
    <secondary_id>NCI-G01-2042</secondary_id>
    <nct_id>NCT00028964</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer</brief_title>
  <official_title>A Randomized, Double Blind, Pacebo-Controlled Study to Assess The Feasibility, Toxicity And Efficacy (Phase I/II) Of A Chinese Herbal Therapy (CHT) For Symptom Management In Women Undergoing Chemotherapy For Stage I/II/III Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <brief_summary>
    <textblock>
      RATIONALE: Herbs used in traditional Chinese medicine may decrease the side effects of&#xD;
      chemotherapy.&#xD;
&#xD;
      PURPOSE: Randomized phase I/II trial to study the effectiveness of herbs used in traditional&#xD;
      Chinese medicine in decreasing the side effects of chemotherapy after surgery in women who&#xD;
      have stage I, stage II, or early stage III breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the toxic effects and safety of chinese herbal therapy (CHT) when administered&#xD;
           for toxicity attenuation in combination with adjuvant doxorubicin and cyclophosphamide&#xD;
           in women with stage I, II, or early stage III breast cancer.&#xD;
&#xD;
        -  Determine patient compliance and the feasibility of using CHT by daily treatment&#xD;
           calendars, weekly symptom inventories, and quality of life and mood state questionnaires&#xD;
           completed by these patients.&#xD;
&#xD;
        -  Determine patient preferences and concerns about CHT.&#xD;
&#xD;
        -  Determine, preliminarily, the efficacy of CHT in ameliorating the toxic effects/side&#xD;
           effects of adjuvant chemotherapy with doxorubicin and cyclophosphamide, in terms of the&#xD;
           incidence and severity of adverse events, in these patients.&#xD;
&#xD;
      OUTLINE: This is a randomized, placebo-controlled, double-blind study. Patients are&#xD;
      randomized to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive adjuvant doxorubicin IV and cyclophosphamide IV over 1 hour on&#xD;
           days 0, 21, 42, and 63. Patients also receive oral chinese herbal therapy three times&#xD;
           daily on days -10 to 105.&#xD;
&#xD;
        -  Arm II: Patients receive adjuvant chemotherapy as in arm I and oral placebo three times&#xD;
           daily on days -10 to 105.&#xD;
&#xD;
      Quality of life is assessed at baseline and on days 3, 24, 45, 66, 84, and 105.&#xD;
&#xD;
      Patients are followed at day 105.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 60 patients (30 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2001</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <condition>Drug/Agent Toxicity by Tissue/Organ</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chinese herbs</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed stage I, II, or early stage III breast cancer for which&#xD;
             adjuvant doxorubicin and cyclophosphamide is recommended&#xD;
&#xD;
          -  No metastatic disease&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Over 18&#xD;
&#xD;
        Sex:&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 80-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  AST no greater than 2 times normal&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No evidence of acute ischemic cardiac disease on ECG&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No history of multiple severe food or medicine allergies or sensitivities&#xD;
&#xD;
          -  No medical or psychological condition that would preclude study participation&#xD;
&#xD;
          -  No severe concurrent illness&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  At least 3 weeks since prior investigational agents&#xD;
&#xD;
          -  At least 3 weeks since prior herbal therapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent herbal therapy or alternative medicine&#xD;
&#xD;
          -  Concurrent acupuncture allowed&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hope S. Rugo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115-1710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2011</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 20, 2011</last_update_submitted>
  <last_update_submitted_qc>February 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2011</last_update_posted>
  <keyword>stage I breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>recurrent breast cancer</keyword>
  <keyword>drug/agent toxicity by tissue/organ</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

